Author: jezzabellemente

Combining Historical Images and Real Life Surroundings in Panoramas Using Augmented Reality Technology Bringing you into Old Hong Kong to Immerse in Fascinating Historical Scenes

With New Check-in Spots and Brand-new Elements of Hong Kong Films

HONG KONG, June 7 (Bernama-BUSINESS WIRE) — The Tourism Commission launched additional spots for the City in Time tourism project in six designated locations in Lei Yue Mun today (June 5). Locals and tourists can simply use their smartphones with the City in Time mobile app downloaded and scan the AR markers installed at designated locations using their smartphones with the City in Time mobile app downloaded to step into the historical panoramas pieced together from heritage photos or illustrations by local artists based on historical information. This immersive journey allows you to witness Hong Kong’s extraordinary geographical and environmental transformation over time, juxtaposing past and present and fully immersing in the old and the new!

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20240605970926/en/

Commissioned by the Tourism Commission, the City in Time Project is developed and produced by the School of Creative Media of City University of Hong Kong (CityUHK). The historical panoramas were modelled in 3D, deploying augmented reality (AR) and multimedia technologies to optical track and spatially align them with the actual environment. Coupled with engaging animations and special sound effects, it offers locals and tourists a comprehensive and immersive travelling experience.

The Secretary for Culture, Sports and Tourism, Mr Kevin Yeung, said, “With ‘Tourism is everywhere in Hong Kong’, City in Time allows locals and tourists to experience Hong Kong’s past and present through the City in Time mobile app. The Project covers designated locations in Central, the Peak, Tsim Sha Tsui, Sham Shui Po, Yau Ma Tei, Jordan and Lei Yue Mun. It will be extended to Tai Hang and Kowloon City later on, tying in with the new trend of city walk and in-depth travel, as well as enriching tourists’ travelling experience.” Professor Jeffrey Shaw, Artistic Director of the Project, also said, “City in Time puts Hong Kong at the forefront of a new media technologically enriched tourism industry. It is the world’s first comprehensive deployment of AR technology in the urban environment, robustly designed to enhance people’s experience of the city’s past and present.”

City in Time was first launched in 2021 at 28 designated locations in Central, the Peak, Tsim Sha Tsui, Sham Shui Po, Yau Ma Tei, and Jordan, where it received widespread acclaim. This time, in addition to expanding to Lei Yue Mun, the mobile app’s features have been upgraded. These upgrades include adding filters and video recording to the selfie function, and advancing the animation of the historical panoramas to 3D.

Six New Check-in Spots: A Closer Look at the Old Days of Lei Yue Mun

The six new designated locations are situated at various viewing decks along the Lei Yue Mun waterfront. Use the mobile app when strolling along the waterfront to scan the AR clocks, locals and tourists can travel back in time to Lei Yue Mun and discover its past in different periods. It feels like entering time tunnel. The six AR clocks depict different historical stories from various periods of Lei Yue Mun, covering themes such as historical and cultural development, development of the seafood and quarrying industries, changes in sea transportation, etc. allowing locals and tourists to explore the cultural history of Lei Yue Mun in depth.

Pilgrimage to Hong Kong Filming Locations: Revisiting the Classics

City in Time has also incorporated film elements at its existing designated locations, encouraging locals and tourists to make pilgrimages to Hong Kong filming locations and watch classic Hong Kong film clips on-site, allowing them to experience the fleeting moments of light and shadow. The films include City on Fire, C’est la vie, mon chéri (Endless Love), Infernal Affairs III, Anita, and A Guilty Conscience, which recently won Best Film at the 42nd Hong Kong Film Awards.

The City in Time mobile app is available for free downloading at the Apple App Store and Google Play. Locals and tourists can also experience it remotely via the City in Time website (cityintime.hk), enjoying the past and present views of various designated locations anytime, anywhere.

High-res images: https://bit.ly/458xt1z

About CITY IN TIME

City in Time brings Hong Kong’s extraordinary history back to life by transforming smartphones into magic ‘augmented reality’ windows contrasting 360-degree panoramic images of old Hong Kong with today’s surroundings.

City in Time can be experienced in person at various designated locations in Hong Kong, using a designated mobile app, or virtually on the City in Time website. The app allows you to use your smartphone camera to compare historical scenes with the present-day situation around you, while the web version compares them to panoramic photographs of the present-day environment. The historical scenes are supplemented with lively animations, informative descriptions of major landmarks, and selfie and sharing functions for uploading to social media platforms.

City in Time can also be experienced remotely on the City in Time website, with the locations virtually accessible.

City in Time is presented by the Tourism Commission and created by the City University of Hong Kong, to enrich the experience of locals and tourists in Hong Kong using the combination of art and technology.

http://mrem.bernama.com/viewsm.php?idm=48762

The HEAD registry, with nearly 800 patients, serves to evaluate the economic and social impact of allergies at a European level 

VALENCIA, Spain, June 4 (Bernama-GLOBE NEWSWIRE) — Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is holding its congress at the Feria de Valencia until Monday, June 3.

“Allergic diseases and asthma are among the most common chronic diseases worldwide and account for a considerable global health burden. However, their real impact is difficult to estimate due to the lack of representativeness and incompleteness of the available data,” explain Dr. Ioana Agache, who chairs EAACI’s Research and Outreach Committee (ROC). The HEAD registry was launched to describe patterns of care for allergic diseases and asthma and to assess their impact on costs, both financial and personal. On average, adult patients lost between 2.68 and 5.33 days of work, children between 14.88 and 24.09 days of school and their families between 3.99 and 23.35 days.

“The significant burden of allergic diseases, according to this research, calls for immediate action to improve their management,” says Dr. Agache. “Treatments advised by EAACI guidelines can improve outcomes, but global clean air measures are needed to make a significant impact,” she points out.

The Congress also discusses how to facilitate the translation of trial and research results into routine clinical practice. “There are some experimental approaches with greater potential to be translated to the clinic, such as flow cytometry for basophil activation tests or ELISA to measure periostin levels,” explains María Escribese Alonso, Vice-Dean of Research at the Faculty of Medicine of the CEU San Pablo University and director of the Institute of Applied Molecular Medicine-Nemesio Diez. She also stresses that Spain is a great country for translational research in allergy “promoting networks where clinicians and researchers have the opportunity to collaborate with a common goal.”

Press Contact EAACI
+41 44 205 55 33
communications@eaaci.org

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/10adb810-ecda-4f52-aa8c-445a31170caa

SOURCE : European Academy of Allergy and Clinical Immunology

· Spectronaut^® 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows
· Novel TrueDiscovery^® P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics
· New TrueTarget^® high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved target identification
· DigitalProteome™ database and Proteoverse™ data exploration tool help extract biological insights for biopharma research

ZURICH, Switzerland and NEWTON, Mass., May 31 (Bernama-GLOBE NEWSWIRE) — Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, has announced the company’s attendance at the American Society for Mass Spectrometry (ASMS) Annual Conference from June 2^nd to June 6^th in Anaheim, CA, where the company will launch Spectronaut 19 and present major scientific and technological advances for its proprietary proteomics research software, services, and data insights solutions.

Biognosys’ scientific presence includes two breakfast seminars, four oral presentations, and eleven posters. In addition, their team of scientific experts will be present at booth #314. Further, Biognosys will participate in the activities of its strategic partner, Bruker, showcasing a comprehensive ecosystem of proteomics solutions at Bruker’s eXceed Symposia, “Multiomics solutions for the post-genomic era” on Sunday, June 2^nd, and Hospitality Suite from Sunday, June 2^nd until Wednesday, June 5^th.

Spectronaut^® 19: Unleashing the Power of AI for Deep, Fast, and Scalable DIA Analysis

This latest release of Biognosys’ flagship software for DIA analysis comes with significant improvements in peptide and protein level identifications, increased depth of candidates’ discovery rate, scalability for large-scale analysis and enterprise use, and extended support for novel workflows.

“While this is one of the feature richest releases we ever had, it’s the improvement in quantification that stands out in Spectronaut 19,” saidLukas Reiter, Ph.D., Chief Technology Officer of Biognosys. “We invested a lot in understanding quantification better, which has clearly paid off. In terms of technologies, improved AI models had a significant impact on this year’s release.”

Jun.-Prof. Dr. Florian Meier-Rosar from University Hospital Jena (UKJ), Faculty of Medicine, stated: “Spectronaut is a great fit for our DIA projects. Its directDIA workflow combines ease of use with reliable quantification which suits our needs when studying protein abundance and post-translational modifications at scale.”

Yansheng Liu, Ph.D., Associate Professor at Yale University School of Medicine, Department of Pharmacology, commented: “Spectronaut is our preferred DIA analysis software due to its high performance and user-friendly interface, which makes analyzing our complex and multiplex DIA datasets both easy and reliable.”

Biognosys’ Breakfast Seminar, “Spectronaut 19: Unlock your data’s true story” on Tuesday, June 4^th is entirely dedicated to this release, featuring presentations by Prof. Josh Coon from University of Wisconsin-Madison, titled “Single-Shot DIA Proteome Analysis: The New Gold Standard for Quantitative Proteomics”, and Denys Oliinyk from Jena University Hospital, titled “Towards High-dimensional Phosphoproteomics with Data-independent Acquisition and µPhos”. In addition, the company will present 3 orals and 3 posters highlighting recent improvements in Spectronaut.

TrueDiscovery^®: now enhanced with groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics

Biognosys is launching a novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type based enrichment with market-leading performance and superior economics. The method offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological, or population proteomics research. The P2 Plasma Enrichment workflow will be available as a CRO service via Biognosys’ TrueDiscovery^® platform, or as an in-house method for high-performance mass spectrometry end-users via licensing.

The technical features and performance data will be presented on Wednesday, June 5^th during the WP 084 poster session and on Monday, June 3^rd during Biognosys’ Breakfast Seminar, “Accelerating Drug Discovery and Development with Biognosys’ Next-Generation Proteomics Services”. This seminar also features presentations by Eric Kuhn from Kymera Therapeutics on “Mass Spectrometry-Based Approaches to Targeted Protein Degradation Drug Discovery and Development” and Alan Shomo from Biogen on “Development of a Quantitative CSF LRRK2 Assay to Support Clinical Studies”.

TrueTarget^®: introducing a high-throughput workflow for large-scale drug target deconvolution screening

A critical challenge in drug development is the high failure rate of candidate drugs in clinical trials. Identifying drug targets and potential off-targets efficiently is crucial. Biognosys’ TrueTarget^® platform, powered by limited proteolysis mass spectrometry (LiP-MS), is a powerful tool for unbiased drug target identification, that is available both as contract research service and licensing option. To facilitate its use for large-scale screening, Biognosys developed an innovative, LiP-MS-HT protocol for automated high-throughput drug target deconvolution that achieves improved target identification and reduced measurement time, with high reproducibility and quantitative precision. Biognosys will present the new LiP-MS-HT workflow during the ThOH Oral Session on Thursday, June 6^th.

DigitalProteome™ and Proteoverse™: turning data into biological insights for biopharma research

Biognosys’ new data insights solution, DigitalProteome™, provides valuable insights into protein expression and significantly enhances in-vivo biomarker discovery and drug development studies. The database includes proteome profiles from 22 healthy tissues from humans, mice, and rats and is readily available as an off-the-shelf library. The key characteristics of the DigitalProteome™ database will be presented on Wednesday, June 5th during the WP 070 poster session. The resource is available for biopharma research via licensing.

To make the rich mass spectrometry data produced by Biognosys’ research service platforms even more accessible and actionable, customers can access the novel Proteoverse™ platform for data visualization and exploration to swiftly extract valuable biological insights, identify key analytes from thousands of proteins, explore peptide-level structures, and examine their biological relevance. The tool will be presented on Thursday, June 6^th during the ThP 119 poster session. The tool is initially available as a free-of-charge service alongside Biognosys’ TrueDiscovery^® research projects.

Visit https://biognosys.com/asms2024 for a complete overview of Biognosys’ presence at ASMS. Posters will be available for download by Friday, June 7.

About Spectronaut^®

Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.

The software employs advanced Search and Artificial Intelligence (AI) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multi-dimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com.

About TrueDiscovery^®

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GCP compliant environment. For more information, visit truediscovery.bio.

About TrueTarget^®

The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.

TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget™ is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.

The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery^®, TrueTarget^®, and TrueSignature^® research service platforms, our flagship software Spectronaut^®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

A photo accompanying this announcement is available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/940b0780-73b6-4c45-84f0-3541e3539ee7

Media Contact

Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 44 244 50 07
yves.serroen@biognosys.com
 
Source: Biognosys AG

–BERNAMA

Global Liver Institute Convenes Fruitful Meeting on the Sidelines of WHA77

Geneva, Switzerland, May 30 (Bernama-GLOBE NEWSWIRE) — Global Liver Institute (GLI) convened esteemed global leaders for an event on the sidelines of the 77th World Health Assembly in Geneva, Switzerland, entitled “Together for Better Liver Health: Amplifying Best Practices Globally,” in partnership with the European Association for the Study of the Liver (EASL). Now in its second year, this exclusive gathering has quickly attracted health leaders from around the world to become a driving force for liver health policy initiatives. 
To complement the event, GLI released Best Practices in Liver Health Policy: A Liver Health is Public Health Report, which evaluates successes that certain countries have had in liver health policy to give insight and promote effective policies worldwide. The report highlights persistent challenges that patients face globally and thoughtful, thorough policies that address these challenges. Drawing examples from Egypt, India, Ireland, Scotland, and Türkiye, it showcases measures such as utilizing primary care data to screen high-risk populations and integrating fatty liver disease into national programs targeting non-communicable diseases.
The more than 100 types of liver disease- driven by a variety of causes from genetic, to viral, to over-exposure to toxic substances – pose substantial challenges for global communities and the health systems that serve them:

· Liver disease causes 2 million deaths per year around the globe.
· An estimated 1.5 billion people in the world have chronic liver disease – an increase of 13% since the beginning of the millennium.
· About 70% of liver cancer is preventable – yet it still faces late diagnosis rates and poor prognosis. 
· Even rare liver diseases appear to be rising in prevalence; in Germany, for instance, the prevalence of the rare disease primary sclerosing cholangitis has risen by around 30% in less than five years.

“We are so grateful to work with such an enduring partner, EASL, and the expert panelists featured, to showcase how addressing liver health aligns with achieving major global public health priorities,” shared Donna R. Cryer, JD, CEO of GLI. “We launched the Liver Health is Public Health Initiative in the UK in 2022 hoping to engage and inspire international leaders and health ministers to deploy the diverse and powerful array of public health tools available to them to the tasks of preventing, identifying, and treating the millions at-risk or living with liver diseases and today is a significant milestone.
In a remarkable display of multi-stakeholder partnership and progress built upon the success of the inaugural event, the event demonstrated the expansion and elevation of the collaboration. For a full list of speakers, including key government figures in health as well as the leaders of internationally renowned organizations, please view the program agenda.
“We are happy to co-host this event alongside GLI and look forward to seeing its reverberating global impact,” shared Aleksander Krag, MD, PhD, MBA; Secretary General, EASL. “It is critical that this event happens in Geneva, Switzerland, on the sidelines of the 77th World Health Assembly, while leaders from each member state work together to prepare next year’s health agenda.”

Attachment
· Together for Better Liver Health

Christine Maalouf
Global Liver Institute
cmaalouf@globalliver.org

Source: Global Liver Institute

–BERNAMA

KUALA LUMPUR, May 21 (Bernama) — Hong Kong Tourism Board (HKTB) has recently unveiled a new docufilm “Hong Kong Classics Reimagined” which premiered during the Marché du Film at the 77th Cannes Film Festival, in France.

According to HKTB in a statement, the 60-minute showcase pays homage to classic Hong Kong movies while igniting the wanderlust of film lovers worldwide.

“The influence of movies reaches far beyond entertainment, igniting travel inspiration and desire. Through “Hong Kong Classics Reimagined”, we pay tribute to timeless classics in Hong Kong’s cinematic history and revitalise them with a fresh burst of energy.

“We hope to inspire audiences from around the world to bring their cinematic dreams to life, creating unforgettable experiences in the captivating city of Hong Kong,” said HKTB Chairman, Dr Pang Yiu-Kai.

The docufilm is a celebration of the rich legacy of filmmaking in Hong Kong which comprises six short films across genres namely thriller, action, comedy, kung fu, romance and art, offering a captivating window into the city’s unique charm and vibrant cultural heritage in full cinematic glory.

Each of the shorts was inspired by some of Hong Kong’s most iconic films and cinema moments, re-imagined by six different directors as a tribute to the city’s most legendary filmmakers.

The shorts feature some of the biggest established and emerging names in contemporary Hong Kong film including superstars Sylvia Chang, George Lam and Karen Mok, which were filmed at some of the city’s most recognisable locations.

In conjunction with the premiere of the docufilm, HKTB has also unveiled a dedicated movie tourism guide on its official website which showcases how travellers can transform their cinematic inspiration into unforgettable experiences in Hong Kong.

— BERNAMA